Efficacy and safety of ultra-long-acting insulin degludec.

about

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.

P2860

Q26784381-FFC168B5-B315-41A5-81C7-4974764689B0 Q38101891-BA7F320D-A6AD-4B5C-A3D8-B8B750B16120 Q38202156-3673A5BB-31EB-4F9F-98BC-26C582718177

P2860

Efficacy and safety of ultra-long-acting insulin degludec.

Item

http://www.wikidata.org/entity/Q38059486

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Efficacy and safety of ultra-long-acting insulin degludec.

@en

type

Item

label

Efficacy and safety of ultra-long-acting insulin degludec.

@en

prefLabel

Efficacy and safety of ultra-long-acting insulin degludec.

@en

P1476

Efficacy and safety of ultra-long-acting insulin degludec.

@en

P2093

Ammar Wakil

http://www.w3.org/2001/XMLSchema#string

P2860

Correlates of insulin injection omission

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

The underuse of insulin therapy in North America.

A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education.

How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study.

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Comment on: Tikhonenko et al. (2010) Remodeling of retinal fatty acids in an animal model of diabetes: a decrease in long-chain polyunsaturated fatty acids is associated with a decrease in fatty acid elongases Elovl2 and Elovl4. Diabetes;59:219-227.

Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.

Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.

P304

55-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2042018812437181

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephen L. Atkin

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233405529

http://www.w3.org/2001/XMLSchema#string

P698

23148194

http://www.w3.org/2001/XMLSchema#string

P932

3474648

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of ultra-long-acting insulin degludec.

about

P2860

P2860

Efficacy and safety of ultra-long-acting insulin degludec.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932